Archive for April, 2008.
Stage IA G 1, 2, 3 Tumor limited to endometrium
Stage IB G 1, 2, 3 Invasion to less than one half of the myometrium
Stage IC G 1, 2, 3 Invasion to more than one half of the myometrium
Stage IIA G 1, 2, 3 Endocervical glandular involvement only
Stage IIB G 1, 2, 3 Cervical stromal invasion
Stage IIIA G 1, 2, 3 Tumor invades serosa and/or adnexa, and/or positive peritoneal cytology
Stage IIIB G 1, 2, 3 Vaginal metastases
Stage IIIC G 1, 2, 3 Metastases to pelvic and/or paraaortic lymph nodes
Stage IVAG 1, 2, 3 Tumor invasion of bladder and/or bowel mucosa
Stage IVB Distant metastases including intraabdominal and/or inguinal lymph nodes
Histopathology–Degree of Differentiation
Canadian pharmacy viagra
Cases of carcinoma of the corpus should be classified (or graded) according to the degree of
histologic differentiation as follows:
G1 = 5% or less of a nonsquamous or nonmorular solid growth pattern
G2 = 6-50% of a nonsquamous or nonmorular solid growth pattern
G3 = more than 50% of a nonsquamous or nonmorular solid growth pattern
Notes on Pathological Grading
1. Notable nuclear atypia, inappropriate for the architectural grade, raises the grade of a grade 1 or grade 2 tumor by 1.
2. In serous adenocarcinomas, clear-cell adenocarcinomas, and squamous cell carcinomas, nuclear grading takes precedence.
3. Adenocarcinomas with benign squamous differentiation are graded according to the nuclear grade of the glandular component.
Rules Related to Staging
Generic pharmacy online
1. Because corpus cancer is now staged surgically, procedures previously used for determination of stages are no longer applicable, such as the findings from fractional dilation and curettage to differentiate between stage I and stage II.
2. It is appreciated that there may be a small number of patients with corpus cancer who will be treated primarily with radiation therapy. If that is the case, the clinical staging adopted by FIGO in 1971 would still apply, but designation of that staging system would be noted.
3. Ideally, width of the myometrium should be measured along with the width of tumor invasion.
Many of the prognostic factors noted above require surgical staging for adequate delineation. Until 1988, staging for endometrial cancer was clinical. It became readily apparent that clinical staging failed to identify the true extent of disease in a large number of patients. Up to one fourth of patients who were thought to have clinical stage disease I had extrauterine disease when surgical staging was done. The margin of error for stage II was even greater, with studies suggesting that 50-60% of patients who were thought to have stage II disease in fact did not. In many instances, the patients had only stage I disease. This misclassification resulted in radiation therapy that probably was unnecessary. Because of lack of sensitivity of clinical staging, FIGO in 1988 determined that corpus cancer should be surgically staged (see the box). Initially, concern was voiced that a considerable number of patients with this disease were elderly and could not withstand the surgical procedure or were quite obese, making surgery technically difficult to perform. Experience has shown that this number appears to be very small. With surgical staging, more specific postoperative therapy, if indicated, could be optimally identified and directed. The role of preoperative radiation in this disease entity has become minimal.
Cialis professional pills
Endometrial cancer is a surgically staged disease, and many of the traditional diagnostic procedures advocated before 1988 are no longer necessary. These include a fractional dilation and curettage and endocervical curettage. A chest X-ray is important pretreatment and could affect final staging. Other scanning techniques, unless clinically indicated, are not advocated on a routine basis.
Viagra Soft Tabs
Surgical staging consists of primary total abdominal hysterectomy and bilateral salpingo-oophorectomy as well as full surgical staging. This includes peritoneal cytology on opening the abdomen, surgical exploration of the abdominal contents, appropriate biopsies, and bilateral pelvic and paraaortic lymphadenectomy. The universal role of the lymphadenectomy continues to be debated, particularly in patients with well-differentiated adenocarcinomas that are superficially invasive. Data suggest that the chance of lymph node metastasis in this group of patients approaches zero, although some authors have found occasional metastasis in this group of patients. The incidence of nodal metastasis, both pelvic and paraaortic, in patients with poorly differentiated or deeply invasive lesions is high enough to warrant the added surgical procedure. Although this lymphadenectomy was originally termed “selective” or “limited,” it is felt that a fairly thorough lymphadenectomy should be performed. Some investigators have suggested that lymph nodes on top of the vessels from the inguinal ligament to the retroperitoneal duodenum should be removed as well as those from the obturator space above the nerve. Numerous nodes should be obtained with such a procedure. The practice of identifying clinically enlarged nodes as those to be removed should not be advocated because the vast majority of metastases to lymph nodes from carcinoma of the uterus are usually microscopic. Such a practice can create a false sense of security.
Multiple prognostic factors have been identified in endometrial adenocarcinoma. Patient age, histology, degree of differentiation, depth of invasion, and surgical staging are all important prognostic factors. Younger patients have a better prognosis than older individuals. This may be because younger patients tend to have a better-differentiated, superficially invasive cancer. Adenocarcinoma with its variants are by far the most common histologic type. Current data suggest that grade of adenocarcinoma is a more important prognostic indicator than presence of a squamous component.
Viagra professional at online canadian pharmacy
Uterine papillary serous carcinoma is recognized as a distinct, highly aggressive carcinoma of the uterus. Patients tend to be older, parous, not obese, and with a high tumor grade. Extrauterine disease is identified frequently with uterine papillary serous carcinoma. Even when disease appears to be limited to the uterus, prognosis is considerably poorer than with adenocarcinoma of similar extent. Fortunately, these tumors are unusual; however, they appear to be diagnosed with increasing frequency. Clear-cell carcinomas occur infrequently, and most studies suggest that clear-cell carcinomas have a poorer prognosis than pure adenocarcinomas.
Herbal phentermine without prescription
The differentiation of the adenocarcinoma has long been recognized as an important prognostic factor. Surgical stage I disease survival is directly related to the grade of the tumor. The grade of the tumor correlates generally with the depth of uterine muscle invasion. As the tumor becomes less differentiated, the chances of deep myometrial involvement increase. These two factors correlate well with extrauterine disease. As a general rule, cancers that are poorly differentiated are associated with greater adnexal and lymph node metastasis and other extrauterine spread. This is also true as the depth of myometrial invasion increases. The role of full surgical staging in determining true extent of the disease becomes apparent. Most studies suggest that the presence of malignant cells in peritoneal cytology is a poor prognostic factor. Tumor cells found in capillary-like spaces within the myometrium have been shown to be predictive of extrauterine metastasis, particularly to the lymph nodes. Other prognostic factors that have been suggested include hormone receptor status, tumor ploidy analysis, and S-phase fraction. Although predictive of prognosis, they have not generally been used in the routine evaluation of endometrial cancer.
The latter two studies have received tremendous notoriety. They are the National Surgical Adjuvant Breast Project study and the Stockholm study. A total of 42 corpus cancers were reported in these two studies. Approximately 5,000 patients taking tamoxifen for various periods and at different doses were compared with patients not taking tamoxifen. The number dropped to 14 using a very conservative latency period of 2 years, as well as elimination of non-adenocarcinoma malignancies, those who were randomized to take tamoxifen but never did, and the patient who was said to have endometrial cancer but on evaluative histology was thought not to. Many of the patients had the diagnosis of corpus cancer made within a very short time of taking tamoxifen (2 months). Obviously, the endometrial cancer was not caused by tamoxifen. Over the last 10 years in the world’s literature, 250 endometrial cancers were identified. During that time, it has been estimated that about 3 million women took tamoxifen for some 7 million woman-years of use. In the United States during this time frame there have been approximately 365,000 women with corpus cancer. All patients who may have had tamoxifen-associated endometrial cancer have not been reported in the literature; however, these numbers would suggest that if tamoxifen is associated with endometrial cancer, that relationship is very minimal. It should also be remembered that women who have breast cancer are also at an increased risk for endometrial cancer (at least twofold to threefold increase). Women with breast cancer should have annual gynecologic examinations, including Pap tests and bimanual and rectovaginal examinations. Although any abnormality should be evaluated, data do not support routine annual biopsies for women taking tamoxifen.
Canadian hgh
Diagnosis
The cost of screening for adenocarcinoma and its precursors in the total population would be prohibitive. The most common symptom of corpus cancer is uterine bleeding. Of all endometrial cancers, 75% occur in the postmenopausal patient, although only 20% of postmenopausal women will have a genital malignancy. As the patient’s age increases after menopause, there is a greater probability that the postmenopausal bleeding is due to a malignancy.
Spermamax news
Irregular bleeding during the perimenopause may be interpreted by both the patient and physician as “going through the menopause.” The menstrual bleeding should become lighter and less frequent as a women goes through this time. Any other bleeding should be evaluated as if she were having postmenopausal bleeding. In the premenopausal patient, the high index of suspicion should be maintained if a diagnosis of endometrial cancer is made. Prolonged heavy menstrual periods or intermenstrual spotting may suggest further evaluation. Many premenopausal patients with adenocarcinoma of the endometrium are obese and anovulatory.
Cheap cialis online
An in-office endometrial biopsy is probably the simplest and easiest way to rule out endometrial cancer. Adequate specimens should be obtained for proper evaluation. If cancer is not present, then further evaluation is probably not needed unless the patient continues to be symptomatic. A formal dilation and curettage, which used to be routine for postmenopausal bleeding evaluation, is no longer justified as the first diagnostic procedure. Many clinicians advocate dilation and curettage for women who have atypical hyperplasia because a considerable number of these women will have a coexistent, well-differentiated adenocarcinoma of the endometrium. Although vaginal ultrasonography may accurately identify endometrial thickness, there is no agreement regarding the thickness of endometrium that should cause concern. Some researchers have suggested 3 mm, others 5 mm or even 8 mm. In the patient not taking tamoxifen, 10 mm or more should prompt an endometrial biopsy. In patients who have been taking tamoxifen, very thick endometriums (eg, 20, 30, or 40 mm) have been described. It now appears that a thick endometrium is a false-positive indicator, because ultrasonography of the uterine cavity after saline instillation (sonohysterogram) has shown that this thickness may be due to large polyps or thickened proximal myometrium falsely identified as endometrium. Hysteroscopy has also been suggested as an accurate way of identifying significant endometrial pathology. Hysteroscopy can be performed easily in the office; however, the accuracy depends upon operator skill. If lesions are seen, biopsies are then taken. The endometrial biopsy may be the best diagnostic procedure, with ultrasonography and hysteroscopy reserved if further evaluation if needed.
Screening and Etiology
Cancer of the uterine corpus is the most common gynecologic malignancy. Approximately 36,000 women per year develop uterine cancer in the United States, making it the fourth most common cancer in women. Unopposed estrogen use results in a fourfold increase in adenocarcinoma of the endometrium. Fortunately, the use of progestins has decreased this risk by approximately 50%.
Generic viagra information
The incidence of endometrial cancer in the United States is approximately 0.7 per 1,000 women. Screening and autopsy studies suggest that there may be many occult, undiagnosed endometrial cancers because they are asymptomatic.
Endometrial adenocarcinoma occurs during both the reproductive and the menopausal years. The median age of onset is 61 years; the largest number of affected patients are between the ages of 50 and 59 years. Almost one fourth of all adenocarcinomas of the endometrium are diagnosed before menopause.
Cheap hgh online
Multiple factors have been associated with adenocarcinoma of the endometrium. The use of combination oral contraceptives decreases the risk of endometrial cancer. Women who use oral contraceptives have a 0.5 risk ratio (relative risk) of developing endometrial cancer compared with those who have never used oral contraceptives. This protection occurs with as little as 12 months of use, and protection continues for at least 10 years. The use of oral contraceptives is believed to prevent about 2,000 cases of endometrial cancer each year.
Tramadol online pharmacy
Two distinct phenotypes are associated with the onset of endometrial cancer. The first is women with late-onset menopause who are obese and nulliparous. If all three factors are present, the risk for developing endometrial cancer is increased by about fivefold. Such patients tend to have well-differentiated, superficially invasive cancer for which simple hysterectomy and bilateral salpingo-oophorectomy are therapeutic, with a long-term survival rate of 95% or greater. Several studies have suggested that of these women who develop endometrial cancer, those who were taking estrogen therapy have just as good, if not longer, survival rates as those who were not taking estrogen therapy.
A second phenotype is characterized as nonestrogenic. These women tend to be multiparous, thin, and African American, and they usually have histologically poorly differentiated, deeply invasive lesions that may have an extrauterine extent. The prognosis of these women is considerably worse and may account for decreased survival rates in African-American women compared with the rates for white women.
There is growing concern that the increased use of tamoxifen for therapeutic and prophylactic indications in breast cancer may lead to an increased number of endometrial cancers. Tamoxifen is an antiestrogen that competes with estrogen at the receptor site. Other modes of action such as growth factors could be just as important or more so than its competitive action at the receptor site. It appears that specific end organs in the genital tract may respond to tamoxifen in an entirely different manner than do the breasts. In the premenopausal patient, serum estradiol levels can be much higher than estradiol’s peak level during the menstrual cycle, yet atrophic changes in the vagina and uterus are present. In postmenopausal women, it appears that tamoxifen produces a stimulatory effect on the uterus, yet atrophic changes in the vagina are noted and significant vasomotor symptoms are present.
Canadian Zithromax
All of the prospective, randomized studies that identified endometrial cancers in breast cancer patients receiving tamoxifen therapy were designed to evaluate the efficacy of the drug in breast cancer, but did not examine the safety issues of the drug. Patients taking tamoxifen therapy develop uterine bleeding and have other gynecologic symptoms to a greater degree than those not taking tamoxifen. Prospective, randomized studies comparing the number of endometrial cancers in the tamoxifen group with the number in the no-tamoxifen group suggest, but do not positively identify, a relationship between tamoxifen and this cancer. To date, 15 studies have compared tamoxifen either with placebo or no drug in varying doses for different time intervals with nonuniform median follow-up times. Of these studies, 12 noted no difference in the number of endometrial cancers between the tamoxifen and the no-tamoxifen groups, one noted a significantly decreased incidence of endometrial cancer in the tamoxifen group, and two noted an increased number of corpus cancers in the tamoxifen group.
Canadian pharmacy
Posted on April 3rd, 2008 by Canadian Health in
Melanoma A randomized adjuvant trial of GM2/BCG given following surgery for stage III melanoma (AJCC staging) has been conducted in 122 patients at Memorial-Sloan-Kettering Cancer Center (MSKCC) between 1987 and 1988. This trial, reported at more than 5 years of follow-up, has demonstrated the induction of IgM anti-GM2 antibodies in a majority of patients who were immunized, and the presence of native antibodies against GM2 in a small (fewer than 5%) subset of unvaccinated patients in the control group. Antibody response against GM2 was again demonstrated to be a highly significant and favorable prognostic factor. In addition, vaccination was associated with a prolongation of relapse-free survival of borderline statistical significance, confounded by the occurrence of native anti-GM2 antibody responses among six patients in the total, five of whom were entered into the control group. Analysis of the efficacy of immunization among seronegative entrants into this protocol revealed a significant improvement of relapse-free survival associated with GM2/BCG vaccination ( P = .02).
Generic viagra pills online
To further augment the immunogenicity of GM2, a variety of measures have been explored. Covalent attachment of GM2 to carrier proteins, such as keyhole limpet hemocyanin (KLH), has improved the titer and durability of the IgM response seen with BCG and GM2 and induced antibody of the IgG isotype for the first time. A phase-III evaluation of the GM2-KLH vaccine with the QS21 adjuvant has been planned in the ECOG and US Intergroup mechanism, as well as in England.